Last reviewed · How we verify

Dual Trigger

Weill Medical College of Cornell University · FDA-approved active Small molecule

Dual Trigger is a protocol combining a GnRH agonist and hCG injection to induce final oocyte maturation in assisted reproductive technology.

Dual Trigger is a protocol combining a GnRH agonist and hCG injection to induce final oocyte maturation in assisted reproductive technology. Used for Final oocyte maturation triggering in IVF cycles, Reduction of ovarian hyperstimulation syndrome (OHSS) risk in high-responder patients.

At a glance

Generic nameDual Trigger
Also known asDual ovulation trigger (Choriomon and Triptorelin)
SponsorWeill Medical College of Cornell University
Drug classReproductive hormone protocol
TargetGnRH receptor and LH receptor
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhaseFDA-approved

Mechanism of action

The dual trigger approach uses both a GnRH agonist and human chorionic gonadotropin (hCG) administered together or in sequence to trigger the final maturation and release of eggs during in vitro fertilization (IVF) cycles. This combination has been shown to improve oocyte maturation rates and reduce ovarian hyperstimulation syndrome (OHSS) compared to hCG trigger alone, particularly in high-risk patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results